A North Carolina court has ruled on a significant case involving BIOMILQ, Inc., a company specializing in human cell-cultured technologies, and Shayne Guiliano, a former partner. The North Carolina Business Court addressed allegations of trade secret theft and trademark infringement in its decision on case number 22-CVS-255. The ruling has implications for how companies protect their intellectual property and manage disputes with former partners.

The court's opinion, issued by Judge Michael L. Robinson, partially granted Guiliano's motion to dismiss BIOMILQ's claims, particularly regarding the misappropriation of trade secrets. This ruling affects both BIOMILQ and Guiliano, as it clarifies the legal standards for trade secret protection and the requirements for alleging such claims.

Background

BIOMILQ, Inc. is a Delaware corporation based in Durham, North Carolina, founded in January 2020 by Dr. Leila Strickland and Michelle Egger. The company focuses on developing cell-cultured human milk products. Shayne Guiliano, a former partner of Dr. Strickland, co-founded 108Labs, LLC, in 2013 with her. The dispute arose when Guiliano allegedly photographed pages from a notebook belonging to Dr. Strickland, which contained confidential information related to BIOMILQ's research and development.

The case began when BIOMILQ filed a complaint against Guiliano and 108Labs in March 2022, accusing them of misappropriating trade secrets, trademark infringement, and other claims. Guiliano responded with a motion to dismiss, arguing that the allegations were insufficient to support BIOMILQ's claims. The court's ruling now provides clarity on the legal standards surrounding these issues.

The Ruling

The court ruled on the defendants' joint motion to dismiss the Amended Complaint, which included seven claims for relief. While the court dismissed the claim for misappropriation of trade secrets, it allowed the common law trademark infringement claim to proceed. Judge Robinson stated, "BIOMILQ has satisfied the pleading requirements for this claim to survive the Motion, and therefore the Motion is DENIED with respect to Count Two." This means that BIOMILQ can continue to pursue its trademark infringement claim against Guiliano and 108Labs.

However, the court found that BIOMILQ failed to adequately demonstrate that it took reasonable steps to protect the confidentiality of its trade secrets. Judge Robinson noted, "the measures BIOMILQ took to maintain the secrecy of the Notebook are unreasonable under the circumstances." As a result, the court dismissed the trade secret misappropriation claim without prejudice, allowing BIOMILQ the opportunity to amend its allegations if it can provide sufficient facts to support its claims.

Impact

This ruling has significant implications for BIOMILQ and similar companies. It highlights the importance of taking concrete steps to protect trade secrets and the necessity of clearly defining what constitutes a trade secret in legal filings. The court's decision also emphasizes that general assertions of confidentiality may not be sufficient to survive a motion to dismiss.

For Guiliano and 108Labs, the ruling allows them to continue to defend against the trademark infringement claim, which could have broader implications for their business operations. The outcome of this case could set a precedent for how trade secrets are protected in North Carolina and beyond, particularly in the biotechnology sector.

What's Next

BIOMILQ has the option to appeal the court's decision regarding the dismissal of its trade secret claim or to amend its complaint to address the deficiencies noted by the court. The case will continue as BIOMILQ pursues its trademark infringement claim against Guiliano and 108Labs. The ongoing legal battle underscores the complexities of intellectual property law and the challenges companies face in protecting their innovations.